Objective. To analyze the efficacy and safety of submucosal tunnel endoscopic resection (STER) for the treatment of submucosal masses in esophageal muscularis propria. Method. A total of 272 patients with submucosal masses in esophageal muscularis propria diagnosed and treated in our hospital from February 2019 to January 2022 were randomly selected for the study and then were randomly divided into the STER group ( n = 136 ) and the endoscopic mucosal dissection (ESD) group ( n = 136 ) according to the random number table method. Patients in the STER and ESD groups were treated with STER and ESD, respectively. The clinical data of patients from the two groups were collected and compared. The clinical effects and the changes of surgery-related indexes of patients after ESD and STER treatment were observed. The safety of ESD and STER was compared. The factors influencing the efficacy of STER treatment for submucosal masses in esophageal muscularis propria were analyzed. Result. There were significant differences between the STER group and the ESD group in terms of tumor size, lesion level, adhesion and surgical approaches ( P < 0.05 ). The effective rates of ESD treatment and STER treatment were 98.53% and 88.97%, respectively. Meanwhile, the effective rates of STER treatment were significantly higher than those in the control group ( P < 0.05 ). In addition, the patients in the STER group had longer operation time, less blood loss, and shorter hospital stay compared with those in the ESD group ( P < 0.05 ). Adverse reactions occurred during ESD treatment and STER treatment included delayed bleeding, adhesion, perforation, and pleural effusion with the total incidence of adverse reactions of 4.41% and 13.97%, respectively. The adverse reactions in STER group were prominently less than these in the ESD group ( P < 0.05 ). Logistic multivariate regression analysis showed that independent risk factors, including tumor size, lesion level, adhesion, and surgical approaches, affected the efficacy of STER in the treatment of submucosal masses in esophageal muscularis propria ( P < 0.05 ). Conclusion. STER is an effective method for the treatment of submucosal masses in esophageal muscularis propria, which can exhibit a good effect with faster postoperative recovery and higher safety, thereby being worthy of clinical application and promotion. Tumor size, lesion level, adhesion, and surgical approaches are all related factors affecting the effect of STER treatment.
To explore the clinical application value of narrow band imaging (NBI) in the early screening of colorectal cancer. 200 patients were selected as the research objects, and were divided into test group and control group by the randomization method, within 100 cases in each group. The patients in the test group were examined by NBI, while the patients in the control group were examined by ordinary endoscopy, and then the lesion detection rate, image definition and pathological examination results of the two groups were compared. After the patients in the test group received NBI examination, the lesion detection rate, image definition and lesion detection coincidence rate were significantly higher than those of the control group, and the comparative difference between the two groups was statistically significant (P < 0.05). NBI examination of colorectal mucosa can clearly show the pit pattern and the morphological structure of capillaries of the early colorectal cancer and its precancerous lesions, thus effectively improving the diagnosis rate of early colorectal cancer and its precancerous lesions, playing a good clinical application value in the early screening of colorectal cancer, and guiding the later treatment, so it is suitable for clinical promotion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.